Category Archives: Parkinson’s Treatment

Living well with Parkinsons 2014 - Introduction and Panel Presentations Living well with Parkinsons 2014 - Introduction and Panel Presentations Living Well with Parkinson's 2014 Introduction and Panelists Presentations Moderated by... By: PANC Videos … Continue reading →

NEW YORK (TheStreet) -- Shares ofNeuroDerm (NDRM) plunged 21.71% to $14.20 on higher-than-average volume on Wednesday, as the stock sold offone day after it soared following the Israeli company's announcement of encouraging results from a trial for a treatment of Parkinson's disease. NeuroDerm announced continuous, subcutaneous dosage of two of its proprietary liquid levodopa/carbidopa (LD/CD) product candidates, ND0612H and ND0612L, resulted in clinically significant plasma levadopa levels. The dataindicates that the high dose version, ND0612H, meant for patients with severe Parkinson's disease, could be an effective therapy alternative to current treatments that require surgery. "Maintaining consistent levodopa concentrations has been the most significant hurdle in Parkinson's disease therapy," said Sheila Oren, MD, NeuroDerm's Vice President of Clinical and Regulatory Affairs. Exclusive Report: Jim Cramer's Best Stocks for 2015 Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade. Access the tool that DOMINATES the Russell 2000 and the S&P 500. Jim Cramer's protg, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar. Continue reading here: NeuroDerm (NDRM) Stock Plunges Today Following Tuesday's Gains … Continue reading →

NEW YORK (MarketWatch) -- NeuroDerm Ltd. shares NDRM, +193.53% surged almost 20% in premarket trade Tuesday, after the company announced promising results from a trial of a treatment for Parkison's disease. The Israeli company said continuous, subcutaneous delivery of two liquid product candidates had a positive effect on plasma levels, suggesting the high dose version that is aimed at severe sufferers of the disease may be an effective alternative to current treatments that require surgery. The higher dose candidate, known as ND0612H, "is designed to be delivered continuously, thus we believe it should offer a simple and effective treatment option that will minimize the need for surgical intervention in advanced Parkinson's patients," Sheila Oren, vice president of clinical and regulatory affairs at the company, said in a statement. Shares of NeuroDerm, which went public in November, are down 15.2% on the month, while the S&P 500 has gained 1.1%. Excerpt from: NeuroDerm stock surges almost 20% as Parkinson's treatment shows promise … Continue reading →

NEW YORK (TheStreet) -- Shares ofNeuroDerm (NDRM) skyrocketed more than 65% to a 52-week high of $10.31 in morning trading Tuesday after the Israeli company announced encouraging results from a trial for a treatment of Parkinson's disease. NeuroDerm announcedcontinuous, subcutaneous dosage of two of its proprietary liquid levodopa/carbidopa (LD/CD) product candidates, ND0612H and ND0612L, resulted in clinically significant plasma levadopa levels. The data indicates thatthe high dose version, ND0612H, meant for patients with severe Parkinson's disease, could be an effective therapy alternative to current treatments that require surgery. "Maintaining consistent levodopa concentrations has been the most significant hurdle in Parkinson's disease therapy," said Sheila Oren, MD, NeuroDerm's Vice President of Clinical and Regulatory Affairs. Exclusive Report: Jim Cramers Best Stocks for 2015 Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade. Access the tool that DOMINATES the Russell 2000 and the S&P 500. Jim Cramer's protg, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar. View post: NeuroDerm (NDRM) Stock Skyrockets to One-Year High After Encouraging Parkinson's Treatment Results … Continue reading →

Clinical-stage pharmaceutical company NeuroDerm Ltd. (NDRM: Quote), which went public in November, announced Tuesday topline results for a mid-stage study for its proprietary liquid levodopa/carbidopa (LD/CD) product candidates as a treatment for Parkinson's disease. Following the announcement, the company's shares are skyrocketing more than 49 percent in early deals. The company said the continuous, subcutaneous delivery of the liquid product candidates, ND0612H and ND0612L, led to clinically-significant plasma levodopa levels. The company added that ND0612H, the higher dose version, provided an effective alternative to current treatments that require surgery. "Maintaining consistent levodopa concentrations has been the most significant hurdle in Parkinson's disease therapy. The results from this study demonstrate that ND0612H can reach high LD plasma levels that, to date, could only be reached and maintained by products that require surgical intervention," said Sheila Oren, NeuroDerm's Vice President of Clinical and Regulatory Affairs. The phase IIa study was conducted on 16 patients with an advanced form of Parkinson's disease having motor fluctuations that was chronically treated with standard of care oral LD/CD. The primary endpoints of the study were to assess the safety, tolerability and pharmacokinetics (PK) of six dose regimens of ND0612H and ND0612L. The patients were treated with … Continue reading →

Rehovot-based Central Nervous Systems treatment drug developer NeuroDerm(Nasdaq:NDRM) has achieved positive results in a Phase IIa Pharmacokinetic Study of ND0612H and ND0612L for the treatment of Parkinsons disease. These results suggest that the high dose version, ND0612H, intended for severe Parkinsons disease patients, may provide an effective therapy alternative to current treatments requiring surgery. Following publication of the results the company's share price rose 194% to $18.14, giving a market cap of $308 million, well above Neuroderm's share price of $10 at its IPO last month, when it raised $50 million. NeuroDerm VP Clinical and Regulatory Affairs Dr. Sheila Oren said, Maintaining consistent levodopa concentrations has been the most significant hurdle in Parkinsons disease therapy. The results from this study demonstrate that ND0612H can reach high LD plasma levels that, to date, could only be reached and maintained by products that require surgical intervention. ND0612H is designed to be delivered continuously, thus we believe it should offer a simple and effective treatment option that will minimize the need for surgical intervention in advanced Parkinsons patients. NeuroDerm CEO Dr. Oded Lieberman said, These results add to the growing body of clinical data confirming our thesis that continuous, subcutaneous delivery of LD/CD … Continue reading →

Aquinox Pharmaceuticals Inc. (AQXP: Quote) has initiated dosing in a phase II clinical trial of AQX-1125 for the treatment of atopic dermatitis. The trial, dubbed KINSHIP, designed to enroll about 50 adult patients with mild to moderate atopic dermatitis is being conducted at clinical research centers in Canada. AQXP closed Tuesday's trading 6.46% higher at $7.25. ARIAD Pharmaceuticals Inc. (ARIA: Quote) has granted Angelini Pharma exclusive rights to commercialize leukemia drug Iclusig in seven Central and Eastern European countries. The seven countries include Bulgaria, the Czech Republic, Hungary, Poland, Romania, Slovakia and Slovenia. The commercial launches of Iclusig in these Central and Eastern European countries are expected to begin in 2015. With this distributorship in place, Iclusig will be available to patients with resistant and intolerant Philadelphia-positive leukemias in more than 23 countries in Europe. Net product revenues from sales of Iclusig were $14.5 million for the quarter ended September 30, 2014, an increase of 22% from the second quarter of 2014. ARIA closed Tuesday's trading at $6.82, down 1.23%. In after-hours, the stock was up 1.25% at $6.90. Idera Pharmaceuticals Inc.'s (IDRA: Quote) drug candidate IMO-8400 has been granted orphan drug designation by FDA for the treatment of Waldenstrm's … Continue reading →

Patients with Parkinsons, medics and carers have identified the top ten priorities for research into the management of the condition in a study by the University of East Anglia in Norwich and Parkinsons UK. Commissioned by Parkinsons UK, people with direct and indirect personal experience of the condition worked together to identify crucial gaps in the existing evidence to address everyday practicalities in the management of the complexities of Parkinsons. Patients stated that the overarching research aspiration was an effective cure for Parkinsons but whilst waiting for this more research was needed into the management of the condition. Top of the list, which was narrowed down from a list of 94 uncertainties, was the need to identify what treatments help reduce balance problems and falls in people with Parkinsons. This was followed in second place by questioning what approaches are helpful for reducing stress and anxiety in patients, and what treatments help reduce involuntary movements a side effect of some medications in third place. Also outlined in the top ten research priorities for Parkinsons management, published on BMJ Open, are better monitoring methods, improving sleep quality and the need to develop interventions specific to the different types of Parkinsons and … Continue reading →

Medication is the primary treatment for symptoms of Parkinson's. In a few cases, surgery may also be an option. It is very important for you, your family and/or caregivers to develop a solid understanding of the treatment options that may be available. Focusing on exercise, stress management, proper nutrition and other available therapies is also part of living well with Parkinson's. More information can also be found in: Parkinson's Disease: Understanding and Moving Forward Frequently Asked Questions Do I need a Neurologist? According to the Canadian Guidelines on Parkinson's Disease, people suspected of having Parkinson's should be referred to a neurologist for diagnosis and ongoing care. A neurologist is a physician who diagnoses and treats disorders of the nervous system. A medical referral by a family physician or a medical specialist is required for a consultation. The neurologist will report findings to the family physician. Neurologists are located throughout BC, although people living in small towns and rural communities may have to travel some distance for a consultation. Many community neurologists treat a variety of neurological disorders including Parkinson's but they may not specialize in one specific disorder. Continued here: Treatment | Parkinson Society British Columbia … Continue reading →

Even without obvious signs of ill health and medical emergencies being overlooked, the treatment Mr Hubbard received left much to be desired. Staff appeared to have little time to devote to him and he frequently received his medicines late. For sufferers of Parkinsons Disease like Mr Hubbard this can leave them feeling, according to experts, as if they are trapped inside their own bodies and can lead to irreparable damage. Miss Hubbard, 50, who works with the charity Parkinsons UK to raise awareness of the condition, added: Weve got an ageing population and we shouldnt be treating our elderly people like this. The average time people spend in a nursing home is just six months before they die and you have to ask why they seem to decline so quickly? Mr Hubbard entered the home in June 2012, after his condition began to worsen. He had previously been looked after four times a day by carers at the house he shared with his elderly wife in Sunderland, though even at this stage Miss Hubbard had her concerns. George Hubbard (far left) who died while suffering from Parkinson's She said: Me and my brother would go around there to see him … Continue reading →